EUVIMEDEUVIMED entdecken
Open Access

68 Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study

Ling Chen, Shan Zheng, Linying Chen, Sunwang Xu, Kunlin Wu, Lingjun Kong, Jiajie Xue, Xiangjin Chen, Weibing Miao, Youzhi Zhu

Journal of Nuclear Medicine · 2023-12 · 64 (12) · 1899-1905

DOI: 10.2967/jnumed.123.266079 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, online erschienen am 02.11.2023. Verfasst von Ling Chen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China. Hauptthemen laut MEDLINE: Breast Neoplasms, Quinolines. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET/CT has demonstrated promising clinical results, with a higher SUVmax and tumor-to-background ratio (TBR) in breast cancer (BC) patients than 18F-FDG PET/CT. Here, we aimed to evaluate the suitability of 68Ga-FAPI PET/CT for the early and late prediction of the pathologic response to neoadjuvant chemotherapy (NAC) in BC.

Methods

Twenty-two consecutive patients with newly diagnosed BC and an indication for NAC were prospectively included. All patients underwent standard chemotherapy and 68Ga-FAPI PET/CT at baseline, after 2 cycles of NAC (PET2), and 1 wk before surgery (PET3). SUVmax was measured in the primary tumor region and positive regional lymph nodes. The expression of fibroblast activation protein in the primary lesion was analyzed by immunohistochemistry.

Results

Seven patients (31.8%) achieved a pathologic complete response (pCR), and 15 (68.2%) had residual tumors. Thirteen patients (59.1%) showed concentric withdrawal of the primary tumor, and 9 (40.9%) showed diffuse withdrawal. Between PET2 and PET3, the ΔSUVmax of the primary tumor (R 2 = 0.822; P = 0.001) and metastatic lymph nodes (R 2 = 0.645; P = 0.002) were significantly correlated. The absolute values of SUVmax and TBR at PET2 and PET3 were lower in patients with pCR than in those without pCR (P < 0.05). Moreover, a larger ΔSUVmax at any time point was strongly associated with pCR (P < 0.05). Similar downward trends in SUVmax, TBR, and ΔSUVmax were observed in the pattern of primary tumor reduction. For predicting pCR, the optimal cutoff values for ΔSUVmax after 2 chemotherapy cycles, ΔSUVmax before surgery, TBR after 2 chemotherapy cycles, and TBR before surgery of the primary tumor were 3.4 (area under the curve [AUC], 0.890), 1.1 (AUC, 0.978), -63.8% (AUC, 0.879), -90.8% (AUC, 0.978), 7.6 (AUC, 0.848), and 1.4 (AUC, 0.971), respectively. Immunohistochemistry showed that the SUVmax and TBR of 68Ga-FAPI PET/CT were positively correlated with fibroblast activation protein expression (P < 0.001 for both).

Conclusion

Assessment of early changes in 68Ga-FAPI uptake during NAC by 68Ga-FAPI PET/CT can predict pCR and primary tumor concentric withdrawal in BC patients. 68Ga-FAPI PET/CT has great potential for the early and late prediction of the pathologic response to NAC in BC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsQuinolinesHumansFemalePositron Emission Tomography Computed TomographyProspective StudiesGallium RadioisotopesNeoadjuvant TherapyFluorodeoxyglucose F18RadiopharmaceuticalsFibroblasts

Stichwörter der Autor:innen

68Ga-FAPIbreast cancerfibroblast activation protein inhibitorneoadjuvant chemotherapypathologic response

Substanzen

Gallium RadioisotopesFluorodeoxyglucose F18RadiopharmaceuticalsQuinolines

Autor:innen und Institutionen

  • Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
  • Department of Pathology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China; and.
  • Department of Thyroid and Breast Surgery, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China; zhu@fjmu.edu.cn miaoweibing@126.com.
  • Department of Nuclear Medicine, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China; zhu@fjmu.edu.cn miaoweibing@126.com.
  • Department of Thyroid and Breast Surgery, National Regional Medical Center, Binhai Campus of The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.

Zitieren

APA

Chen, L., Zheng, S., Chen, L., Xu, S., Wu, K., Kong, L., Xue, J., Chen, X., Miao, W., & Zhu, Y. (2023). 68 Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study. Journal of Nuclear Medicine, 64(12), 1899-1905. https://doi.org/10.2967/jnumed.123.266079

Vancouver

Chen L, Zheng S, Chen L, Xu S, Wu K, Kong L, et al. 68 Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study. Journal of Nuclear Medicine. 2023;64(12):1899-1905. doi:10.2967/jnumed.123.266079

BibTeX
@article{Chen2023,
  author = {Chen, Ling and Zheng, Shan and Chen, Linying and Xu, Sunwang and Wu, Kunlin and Kong, Lingjun and Xue, Jiajie and Chen, Xiangjin and Miao, Weibing and Zhu, Youzhi},
  title = {68 Ga-Labeled Fibroblast Activation Protein Inhibitor PET/CT for the Early and Late Prediction of Pathologic Response to Neoadjuvant Chemotherapy in Breast Cancer Patients: A Prospective Study},
  journal = {Journal of Nuclear Medicine},
  year = {2023},
  volume = {64},
  number = {12},
  pages = {1899--1905},
  doi = {10.2967/jnumed.123.266079}
}
Kostenlos starten →